GlassScriptPhysician profile
Michael B Rousseau
NPI 1851328660
$26,429.44
in general payments reported to CMS, 2019-2025
52 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $1,353 · 2021: $2,303 · 2022: $2,166 · 2023: $2,199 · 2024: $2,730 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,954 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,375 · Consulting Fee: $4,125 · Travel and Lodging: $2,507 · Honoraria: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,953.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,375.00 |
| Consulting Fee | $4,125.00 |
| Travel and Lodging | $2,507.25 |
| Honoraria | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $17,697.15 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $963.16 | 2019-2025 | Ams 700, Lumenis Pulse 120h, Axonics |
| Urogen Pharma, INC. | $771.60 | 2020-2025 | Jelmyto |
| Astellas Pharma US INC | $705.11 | 2019-2025 | Xtandi, Myrbetriq |
| Neotract INC. | $548.28 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $490.68 | 2020-2025 | Provenge |
| Axonics, INC. | $462.03 | 2020-2024 | Axonics |
| Janssen Biotech, INC. | $451.51 | 2020-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $368.39 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $355.13 | 2021-2024 | |
| Olympus America INC. | $253.65 | 2022-2025 | Itind System |
| Ferring Pharmaceuticals INC. | $240.66 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $237.30 | 2019-2022 | |
| Calyxo, INC. | $224.39 | 2022-2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $197.70 | 2019-2024 | Lynparza, Welireg, Keytruda |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rousseau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.